Matches 1 - 50 out of 384 1 2 3 4 5 6 7 8 >


Match Document Document Title
US20140243263 METHOD OF ENHANCING DIABETES RESOLUTION  
Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an...
US20100317576 METHODS OF ENHANCING DIABETES RESOLUTION  
Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an...
US20150080298 METHOD FOR TREATING HYPERGLYCEMIA  
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting...
US20120094905 Method for Treating Hyperglycemia with GLP-1  
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting...
US20120040899 Method for Treating Hyperglycemia with GLP-1  
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting...
US20100322894 Combination Therapies for Treating Type 1 Diabetes  
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
US20110091543 ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS  
Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed....
US20130085102 PREVENTION OF HYPOGLYCEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS  
A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and(b)...
US20110076317 Rapid establishment and/or termination of substantial steady-state drug delivery  
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative...
US20150105318 ANTIDIABETIC MEDICATIONS  
Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired...
US20130143800 COMBINATION THERAPIES TO TREAT DIABETES  
Provided are methods for treating diabetes comprising administering to a patient a GLP-1 agonist and an iron chelator. In various embodiments, methods are provided for culturing pancreatic beta...
US20140335170 Reduced Mass Metformin Formulations  
The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.
US20120294936 REDUCED MASS METFORMIN FORMULATIONS  
The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.
US20140031282 FORMULATION FOR TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA FOLLOWING GASTRIC BYPASS SURGERY  
An effective combination of 6.25-100 mg of acarbose with a GLP-1 mimetic, such as 5-10 mg exenatide or 0.3-3.0 mg liraglutide.
US20140107019 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION  
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which...
US20130059778 Identification of a Genetic Risk Factor for Diabetes  
Loss of function ankyrin-B variants have impaired function in pancreatic islets and are associated with type 2 diabetes. This finding provides the basis for methods of identifying at-risk...
US20130125886 METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1  
A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like...
US20120322728 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES  
The present invention relates to thiazolidinedione analogues and pharmaceutical compositions that are useful for treating and/or preventing diabetes mellitis, optionally in combination with a...
US20110172149 Method of Regulating Glucose Metabolism, and Reagents Related Thereto  
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia,...
US20150202296 METHOD FOR ADMINISTERING GLP-1 MOLECULES  
The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating...
US20140005106 METHOD FOR ADMINISTERING GLP-1 MOLECULES  
The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating...
US20110178006 METHOD FOR ADMINISTERING GLP-1 MOLECULES  
The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating...
US20140303077 ALBUMIN FUSION PROTEINS  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20120046221 ALBUMIN FUSION PROTEINS  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20110275561 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug  
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with...
US20140073563 FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME  
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to...
US20120142582 Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders  
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central...
US20140038888 PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS  
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment...
US20120277149 PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS  
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment...
US20140235535 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY  
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are...
US20140349923 Compositions And Methods For Treating Diabetes And/Or Obesity  
Compositions are disclosed which comprise one or more of the following; an anthocyanin, an oligosaccharide, a pectin, or a long-chain fatty acid. Such compositions are useful for treating diabetes...
US20150150948 METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT  
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog...
US20130172243 Methods for Treating Diabetes and Reducing Body Weight  
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog...
US20120058938 NUTRITIONAL COMPOSITION INDUCING A POSTPRANDIAL ENDOCRINE RESPONSE  
The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body....
US20120282336 BILAYER TABLET FORMULATIONS  
The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation...
US20140045746 ANTIDIABETIC TRICYCLIC COMPOUNDS  
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment,...
US20110008313 tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS  
The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury...
US20080146490 Glp-1 Analogue Formulations  
The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a...
US20130331323 GLP-1 POTENTIATORS FROM HEDYCHIUM CORONARIUM AND THEIR APPLICATIONS  
A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a...
US20140065241 USES OF (-)-PERHEXILINE  
A method for treating or preventing a disease, condition or state in a subject in need thereof by administering to the subject an effective amount of the (−)-enantiomer of perhexyline or a...
US20110311650 MULTIPLEXED BIOMARKERS OF INSULIN RESISTANCE  
The invention, in some aspects, relates to methods for characterizing glucose-related metabolic disorders. In some aspects, the invention relates to methods and kits useful for diagnosing,...
US20130280209 METHOD FOR TREATING TYPE 1 DIABETES  
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention...
US20130040878 PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF DIABETES TYPE 2 PATIENTS  
The present invention refers to a pharmaceutical combination for use in the treatment of diabetes type 2 patients.
US20140011733 COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES  
The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a...
US20130203666 PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS  
The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
US20130065828 PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS  
The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
US20050124542 Crystallisation of a GLP-1 analogue  
Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.
US20150259416 Methods for treating and/or limiting development of diabetes  
Provided herein are methods and compositions for limiting development of and/or treating diabetes, involving compounds of formula A-B, wherein A is a pancreatic β cell targeting moiety, and B is...
US20130090287 Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents  
The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery...
US20110039768 FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME,  
The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically,...

Matches 1 - 50 out of 384 1 2 3 4 5 6 7 8 >